Biosimilars in rheumatology: understanding the rigor of their development.
Publication
, Journal Article
Goel, N; Chance, K
Published in: Rheumatology (Oxford)
February 2017
This article examines the current landscape of biosimilar development in rheumatology. As misperceptions about biosimilars exist regarding their comparability to the reference products for clinical use, we review the development paradigm with the goal of improving rheumatologists' understanding of the rigor with which biosimilars are developed. With an emphasis on European Union and US markets, it gives an overview of some of the challenges and issues related to biosimilar development that need to be considered by rheumatologists in this increasingly growing therapeutic space.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Rheumatology (Oxford)
DOI
EISSN
1462-0332
Publication Date
February 2017
Volume
56
Issue
2
Start / End Page
187 / 197
Location
England
Related Subject Headings
- United States
- Rheumatology
- Rheumatic Diseases
- Humans
- European Union
- Drug Discovery
- Biosimilar Pharmaceuticals
- Arthritis & Rheumatology
- Antirheumatic Agents
- 3204 Immunology
Citation
APA
Chicago
ICMJE
MLA
NLM
Goel, N., & Chance, K. (2017). Biosimilars in rheumatology: understanding the rigor of their development. Rheumatology (Oxford), 56(2), 187–197. https://doi.org/10.1093/rheumatology/kew206
Goel, Niti, and Kamali Chance. “Biosimilars in rheumatology: understanding the rigor of their development.” Rheumatology (Oxford) 56, no. 2 (February 2017): 187–97. https://doi.org/10.1093/rheumatology/kew206.
Goel N, Chance K. Biosimilars in rheumatology: understanding the rigor of their development. Rheumatology (Oxford). 2017 Feb;56(2):187–97.
Goel, Niti, and Kamali Chance. “Biosimilars in rheumatology: understanding the rigor of their development.” Rheumatology (Oxford), vol. 56, no. 2, Feb. 2017, pp. 187–97. Pubmed, doi:10.1093/rheumatology/kew206.
Goel N, Chance K. Biosimilars in rheumatology: understanding the rigor of their development. Rheumatology (Oxford). 2017 Feb;56(2):187–197.
Published In
Rheumatology (Oxford)
DOI
EISSN
1462-0332
Publication Date
February 2017
Volume
56
Issue
2
Start / End Page
187 / 197
Location
England
Related Subject Headings
- United States
- Rheumatology
- Rheumatic Diseases
- Humans
- European Union
- Drug Discovery
- Biosimilar Pharmaceuticals
- Arthritis & Rheumatology
- Antirheumatic Agents
- 3204 Immunology